TY - JOUR
T1 - Nodal-stage classification in invasive lobular breast carcinoma
T2 - Influence of different interpretations of the pTNM classification
AU - Van Deurzen, Carolien H.M.
AU - Cserni, Gabor
AU - Bianchi, Simonetta
AU - Vezzosi, Vania
AU - Arisio, Riccardo
AU - Wesseling, Jelle
AU - Asslaber, Martin
AU - Foschini, Maria P.
AU - Sapino, Anna
AU - Castellano, Isabella
AU - Callagy, Grace
AU - Faverly, Daniel
AU - Martin-Martinez, Maria Dolores
AU - Quinn, Cecily
AU - Amendoeira, Isabel
AU - Kulka, Janina
AU - Reiner-Concin, Angelika
AU - Cordoba, Alicia
AU - Seldenrijk, Cornelis A.
AU - Van Diest, Paul J.
PY - 2010/2/20
Y1 - 2010/2/20
N2 - Purpose: Application of current nodal status classification is complicated in lobular breast carcinoma metastases. The aim of this study was to define the optimal interpretation of the pTNM classification in sentinel node (SN) -positive patients to select patients with limited or with a high risk of non-SN involvement. Patients and Methods: SN metastases of 392 patients with lobular breast carcinoma were reclassified according to interpretations of the European Working Group for Breast Screening Pathology (EWGBSP) and guidelines by Turner et al, and the predictive power for non-SN involvement was assessed. Results: Reclassification according to definitions of EWGBSP and Turner et al resulted in different pN classification in 73 patients (19%). The rate of non-SN involvement in the 40 patients with isolated tumor cells according to Turner et al and with micrometastases according to EWGBSP was 20%, which is comparable to the established rate for micrometastases. The rate of non-SN involvement in the 29 patients with micrometastases according to Turner et al and with macrometastases according to EWGBSP was 48%, which is comparable to the established rate for macrometastases. Therefore, the EWGBSP method to classify SN tumor load better reflected the risk of non-SN involvement than the Turner et al system. Conclusion: Compared with the guidelines by Turner et al, the EWGBSP definitions better reflect SN metastatic tumor load and allow better differentiation between patients with lobular breast carcinoma who have a limited or a high risk of non-SN metastases. Therefore, we suggest using the EWGBSP definitions in these patients to select high-risk patients who may benefit from additional local and/or systemic therapy.
AB - Purpose: Application of current nodal status classification is complicated in lobular breast carcinoma metastases. The aim of this study was to define the optimal interpretation of the pTNM classification in sentinel node (SN) -positive patients to select patients with limited or with a high risk of non-SN involvement. Patients and Methods: SN metastases of 392 patients with lobular breast carcinoma were reclassified according to interpretations of the European Working Group for Breast Screening Pathology (EWGBSP) and guidelines by Turner et al, and the predictive power for non-SN involvement was assessed. Results: Reclassification according to definitions of EWGBSP and Turner et al resulted in different pN classification in 73 patients (19%). The rate of non-SN involvement in the 40 patients with isolated tumor cells according to Turner et al and with micrometastases according to EWGBSP was 20%, which is comparable to the established rate for micrometastases. The rate of non-SN involvement in the 29 patients with micrometastases according to Turner et al and with macrometastases according to EWGBSP was 48%, which is comparable to the established rate for macrometastases. Therefore, the EWGBSP method to classify SN tumor load better reflected the risk of non-SN involvement than the Turner et al system. Conclusion: Compared with the guidelines by Turner et al, the EWGBSP definitions better reflect SN metastatic tumor load and allow better differentiation between patients with lobular breast carcinoma who have a limited or a high risk of non-SN metastases. Therefore, we suggest using the EWGBSP definitions in these patients to select high-risk patients who may benefit from additional local and/or systemic therapy.
UR - http://www.scopus.com/inward/record.url?scp=77949889331&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77949889331&partnerID=8YFLogxK
U2 - 10.1200/JCO.2009.22.0723
DO - 10.1200/JCO.2009.22.0723
M3 - Article
C2 - 20085942
AN - SCOPUS:77949889331
SN - 0732-183X
VL - 28
SP - 999
EP - 1004
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 6
ER -